Table 2.
Sample clinical annotation in the discovery and validation cohorts
| Variable | Discovery cohort | Validation cohort | P value | |||
|---|---|---|---|---|---|---|
| Sample type | Biopsies | Brushes | Biopsies | Brushes | Biopsies | Brushes |
| Histology | 0.05 | 0.42 | ||||
| Normal | 38/190 (20) | 6/89 (6.7) | 23/105 (21.9) | 0/48 (0) | ||
| Hyperplasia | 30/190 (15.8) | 11/89 (12.4) | 31/105 (29.5) | 9/48 (18.8) | ||
| Metaplasia | 46/190 (24.2) | 15/89 (16.9) | 14/105 (13.3) | 9/48 (18.8) | ||
| Mild dysplasia | 21/190 (11.1) | 9/89 (10.1) | 13/105 (12.4) | 6/48 (12.5) | ||
| Moderate dysplasia | 38/190 (20) | 30/89 (33.7) | 20/105 (19.0) | 18/48 (37.5) | ||
| Severe dysplasia | 12/190(6.3) | 17/89 (19.1) | 4/105 (3.8) | 6/48 (12.5) | ||
| Carcinoma in situ | 1/190 (0.5) | 0/89 (0) | 0/105 (0) | 0/48 (0) | ||
| Tumor | 0/190 (0) | 1/89 (1.1) | 0/105 (0) | 0/48 (0) | ||
| Unknown histology | 4/190 (2.1) | 0/89 (0) | 0/105 (0) | 0/48 (0) | ||
| Current smoker (genomic prediction) | 119/190 (62.6) | 44/89 (49.4) | 38/105 (36.2) | 20/48 (41.7) | 1.80E-05 | 0.47 |
| Progression status | 0.39 | |||||
| Normal/stable | 47/190 (24.7) | 35/105 (33.3) | ||||
| Progressive/persistent | 44/190(23.2) | 20/105 (19.0) | ||||
| Regressive | 30/190 (15.8) | 18/105 (17.1) | ||||
| Unknown | 69/190 (36.3) | 32/105 (30.5) | ||||
Statistical tests between the discovery and validation cohorts within either the biopsies or brushes were performed using two-sided Fisher’s exact tests and percentages are reported. Source data are provided as a Source Data file